TY - GEN A1 - Volkov, Ilan A1 - Seguro, Luciana A1 - Leion, Elaine P. A1 - Kovács, László A1 - Roggenbuck, Dirk A1 - Schierack, Peter A1 - Gilburd, Boris A1 - Doria, Andrea A1 - Tektonidou, Maria G. A1 - Agmon-Levin, Nancy T1 - Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome T2 - Autoimmunity Highlights Y1 - 2020 U6 - https://doi.org/10.1186/s13317-020-00131-3 SN - 2038-3274 SN - 2038-0305 VL - 11 SP - 1 EP - 8 ER - TY - GEN A1 - Roei, Tulchinsky A1 - Boris, Gilburd A1 - Yehuda, Shovman A1 - Milena, Tocut A1 - Eleanor, Zeruya A1 - Ariel, Binyaminov A1 - Tima, Davidson A1 - Büttner, Thomas A1 - Nasser, Abdullah A1 - Michel, Juliane A1 - Rödiger, Stefan A1 - Schierack, Peter A1 - Howard, Amital A1 - Roggenbuck, Dirk A1 - Yehuda, Shoenfeld A1 - Ora, Shovman T1 - CytoBead ANA 2 assay : a novel method for the detection of antinuclear antibodies T2 - Scientific reports N2 - Detection of anti-nuclear autoantibodies (ANA) is based on a two-step algorithm including indirect immunofluorescence (IIF) on HEp2 cells and subsequent reflex/confirmatory testing for specific autoantibodies. Simultaneous cell- and microbead-based autoantibody detection by IIF may be utilized for the evaluation of systemic autoimmune rheumatic diseases (SARDs). In the present study, we assessed the performance of CytoBead ANA 2 in the detection of ANA and ANA-specific autoantibodies, compared to ANA IIF and BioPlex™ 2200. We also tested the ability of CytoBead ANA DFS-70 to identify dense-fine speckled (DFS) pattern associated with anti-DFS70 antibodies in non-SARDs patients. Hundred-twelve routine sera samples were assessed by manual CytoBead ANA 2 for the presence of ANA and specific autoantibodies. In parallel, these samples were analyzed by HEp2 ANA IIF test and a subsequent multiplexed assay BioPlex™ 2200 ANA. Twenty-nine ANA-positive samples obtained from non-SARDs patients and exhibiting DFS pattern by ANA IIF were further tested by CytoBead ANA DFS-70. A substantial agreement was observed between classical ANA IIF and manual CytoBead ANA 2 for the detection of ANA (k = 0.74). Discordant results were mainly associated with the presence of anti-SSA/Ro antibodies detected by CytoBead ANA 2 in ANA IIF negative patients. A good to almost perfect agreement was found between CytoBead ANA 2 and BioPlex™ 2200 for detection of specific antibodies with kappa values ranging from 0.70 to 0.90. Twenty samples (68.9%) obtained from 29 ANA IIF positive without SARDs patients exhibited DFS pattern in CytoBead ANA DFS-70, which confirmed the presence of anti-DFS70 antibodies. The diagnostic performance of manual CytoBead ANA 2 for ANA screening and detection of ANA specific antibodies is comparable to the diagnostic performance of ANA IIF followed by BioPlex™ 2200. This novel one-step assay enables simultaneous ANA screening and confirmation and represents a promising alternative approach to the time-consuming and costly two-tier ANA analysis. KW - Anti-nuclear antibodies KW - Anti-DFS70 antibodies KW - Indirect immunofluorescence KW - Multiplexed assay KW - CytoBead technology Y1 - 2025 U6 - https://doi.org/10.1038/s41598-025-04583-3 SN - 2045-2322 VL - 15 IS - 1 SP - 1 EP - 11 PB - Nature Publishing Group UK CY - London ER -